Trial reportBiomarkers in medicine2021
Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study).
Trial report in Biomarkers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Association Analyses Between theGenes · 2026Article
- Influence of Sex and Cardiometabolic Risk Factors on the High-Sensitivity Cardiac Troponins at the Concentrations Used as the Thresholds for Cardiovascular Risk Stratification in a Presumably Healthy Polish Population.Journal of clinical medicine · 2024Article
- Optimizing the Clinical Use of High-Sensitivity Troponin Assays: A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Cardiac Magnetic Resonance Left Ventricular Filling Pressure Is Associated with NT-proBNP in Patients with New Onset Heart Failure.Medicina (Kaunas, Lithuania) · 2023Article
- Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?Journal of clinical medicine · 2022Review
- High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.